Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.50
Bid: 297.50
Ask: 300.00
Change: -6.00 (-1.98%)
Spread: 2.50 (0.84%)
Open: 313.00
High: 313.50
Low: 296.50
Prev. Close: 302.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Interest in Shares

13 Mar 2008 12:26

Oxford Biomedica PLC13 March 2008 For Immediate Release 13 March 2008 Oxford BioMedica plc ("the Company") Directors' Interest in Shares and Share Options Oxford BioMedica (OXB:L) The Company today announced that on 13 March 2008 thefollowing awards under the Oxford BioMedica plc Long Term Incentive Plan (LTIP)were made to six executive directors. LTIP: Total shares Percentage of number of over which issued shares shares options are under option awarded held (note 1) Alan Kingsman 1,291,871 2,605,404 0.49%Susan Kingsman 565,640 1,643,331 0.31%Michael McDonald 1,017,542 3,087,843 0.57%Andrew Wood 977,533 2,384,974 0.44%Peter Nolan 771,400 1,612,355 0.30%Nick Woolf 788,582 2,434,867 0.45% Note 1: The total shares over which options are held (share options grantedbetween April 2001 and September 2006 and LTIPs awarded since March 2007)following the awards described above. The share price on which the awards were calculated was 22.5p (the closing priceon the day preceding the awards). The LTIP awards are nil-cost options. The LTIPawards are subject to a three year holding period, and are exercisable on thethird anniversary of the award, subject to the satisfaction of a TotalShareholder Return (TSR) performance condition described below. No awards will be released at the testing date for less than median performanceof Oxford BioMedica TSR compared to a comparator group made up of 20 companiesfrom the biotechnology and healthcare sectors. Median performance will result inrelease of 25% of the shares. Upper quartile performance (i.e. greater than 75thpercentile performance) will result in release of 100% of the shares, withstraight line release between these points. If the performance conditions arenot satisfied or partially satisfied at the end of the holding period, the LTIPaward or the balance of the award (as appropriate) not released shall lapse.There will be no re-testing of the performance conditions. Andrew Wood Company Secretary, Oxford BioMedica plc 13 March 2008 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Jan 20212:09 pmRNSBlock Listing Return
4th Jan 20211:41 pmRNSTotal Voting Rights
30th Dec 20209:03 amRNSOXB notes AZ vaccine has been authorised in the UK
1st Dec 202012:17 pmRNSDirector Dealings
1st Dec 20209:02 amRNSTotal Voting Rights
23rd Nov 20208:47 amRNSOXB notes AZD1222 met primary efficacy endpoint
23rd Nov 20207:00 amRNSNon-Executive Director Appointment
9th Nov 20207:00 amRNSOXB and PhoreMost enter gene therapy collaboration
2nd Nov 20209:02 amRNSTotal Voting Rights
30th Oct 20207:00 amRNSAxovant update on AXO-Lenti-PD and virtual R&D day
23rd Oct 202010:27 amRNSDirector Purchase
12th Oct 20205:38 pmRNSHolding(s) in Company
6th Oct 202012:46 pmRNSAxovant update on 2nd cohort of SUNRISE-PD trial
6th Oct 20207:00 amRNSOXB receives approval for fourth suite in Oxbox
5th Oct 202010:59 amEQSEdison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
2nd Oct 202011:52 amRNSTotal Voting Rights
29th Sep 20203:51 pmRNSDirector Dealings
24th Sep 20209:36 amRNSDirector/PDMR Shareholding
22nd Sep 202012:54 pmRNSDirector/PDMR Shareholding
17th Sep 20207:00 amRNSInterim Results
1st Sep 20209:33 amRNSTotal Voting Rights
1st Sep 20207:00 amRNSMaster Supply and Development Agreement with AZ
27th Aug 20207:00 amRNSNotice of Interim Results
25th Aug 20204:46 pmRNSBlock listing Application
3rd Aug 20209:41 amRNSTotal Voting Rights
3rd Aug 20207:00 amRNSOXB signs DMLA with Beam Therapeutics
31st Jul 20207:00 amRNSOXB Signs Clinical Supply Agreement with Axovant
20th Jul 20204:23 pmRNSOXB notes interim results from AZ on AZD1222
3rd Jul 202010:45 amRNSDirector Dealings / Market Share Purchase
2nd Jul 20203:39 pmRNSDirector Dealings / Market Share Purchase
2nd Jul 20201:34 pmRNSDirector Dealings / Market Share Transactions
1st Jul 20206:30 pmRNSHoldings in Company
1st Jul 20203:44 pmRNSBlock listing Return
1st Jul 20209:13 amRNSTotal Voting Rights
30th Jun 20203:23 pmRNSGrant of options
25th Jun 20209:44 amRNSHolding(s) in Company
24th Jun 202011:45 amRNSHoldings in Company
24th Jun 20209:54 amRNSDirector Dealings / Share Disposal – Replacement
24th Jun 20207:00 amRNSDirector Dealings / Market Share Purchase
23rd Jun 20204:46 pmRNSResult of Annual General Meeting
23rd Jun 20202:47 pmRNSAdmission of shares and Total Voting Rights.
23rd Jun 20207:00 amRNSAnnual General Meeting
19th Jun 20203:26 pmRNSInformation in Relation to Annual General Meeting
19th Jun 20207:00 amRNSResult of Placing
18th Jun 20205:33 pmRNSProposed Placing of new Ordinary Shares
8th Jun 20204:01 pmRNSUpdate on Sanofi Ophthalmology Programmes
8th Jun 20207:00 amRNSFive Year Collaboration Agreement signed with VMIC
1st Jun 20209:06 amRNSTotal Voting Rights
1st Jun 20207:00 amRNSDr Roch Doliveux appointed Non-Executive Chairman
28th May 202012:16 pmRNSClinical & Commercial Supply Agreement with AZ

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.